✦ LIBER ✦

68 ANTIVIRAL EFFICACY OF THE NS3 PROTEASE INHIBITOR, GS-9451, NON-NUCLEOSIDE NS5b INHIBITOR, TEGOBUVIR, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS

✍ Scribed by Pol, S.; Jablkowski, M.; Trenkle, J.D.; Kanwar, B.; Bekele, B.N.; Subramanian, M.; McHutchison, J.G.; Flamm, S.L.; Muir, A.J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

865 12 WEEK RESPONSE-GUIDED TREATMENT WI

✍ Marcellin, P.; Manns, M.P.; Janczewska, E.; Muir, A.J.; Wu, X.; Trenkle, J.D.; K 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 57 KB

13 COMBINATION OF THE NS5A INHIBITOR, GS

✍ Everson, G.T.; Di Bisceglie, A.M.; Vierling, J.M.; Hsieh, F.; Trenkle, J.D.; Kan 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Efficacy of boceprevir, an NS3 protease

✍ Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; Da 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 378 KB